Valuation: Novacyt

Market Cap 32.63M 36.72M 30.45M 27.75M 52.35M 3.53B 52.83M 369M 143M 1.8B 138M 135M 5.79B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 34.58M 38.92M 32.28M 29.42M 55.48M 3.74B 56M 391M 151M 1.91B 146M 143M 6.14B EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.07x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-4.66%
1 week-11.24%
Current month-9.09%
1 month-12.11%
3 months+12.36%
6 months+20.81%
Current year+15.09%
1 week 0.44
Extreme 0.445
0.54
1 month 0.44
Extreme 0.445
0.54
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 30/04/2024
Director of Finance/CFO 44 31/12/2019
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Director/Board Member 75 02/07/2006
Director/Board Member 60 26/06/2017
Director/Board Member 44 01/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/26 Buy

Chief Executive Officer

1,792 0.0025%
30/03/26 Buy

Chairman

15,228 0.0216%
30/03/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
-4.66%-11.24%-6.93%-37.11% 36.72M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.67%-1.65%+48.26%+104.54% 39.06B
Weighted average by Cap. +0.12%-0.84%+58.76%+129.89%

Financials

2026 *2027 *
Net sales 30.52M 34.36M 28.49M 25.97M 48.98M 3.3B 49.43M 345M 134M 1.69B 129M 126M 5.42B 34.86M 39.24M 32.54M 29.66M 55.93M 3.77B 56.45M 394M 153M 1.93B 147M 144M 6.19B
Net income - -
Net Debt 1.96M 2.2M 1.83M 1.66M 3.14M 212M 3.17M 22.09M 8.56M 108M 8.27M 8.09M 347M 4.84M 5.45M 4.52M 4.12M 7.77M 524M 7.84M 54.69M 21.19M 268M 20.46M 20.02M 860M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
02/10/26 €0.4500 -4.66% 271,083
01/10/26 €0.4720 -4.65% 377,585
30/09/26 €0.4950 -2.17% 446,734
29/09/26 €0.5060 -1.75% 303,342
28/09/26 €0.5150 +1.58% 128,558

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock